The company reported a profit before tax of Rs 77.72 crore in Q1 FY27 compared with a pre-tax loss of Rs 36.66 crore in Q1 FY26. It also recorded exceptional gains of Rs 97.34 crore during the quarter.
Aditi Panandikar, managing director, Indoco Remedies, said, “The first quarter of the financial year 2026-27 reflects the continued execution of our long-term strategy focused on deliverables from our core businesses despite a dynamic operating environment. The growth in this quarter is due to the resilient domestic formulation business, while our international formulations and API businesses continued to make steady progress.”
Indoco Remedies is a fully integrated, research-oriented pharmaceutical company with a strong global presence. The company's turnover is $175 million with human capital of over 6,000 employees, including over 300 skilled scientists and field staff who are the strength of the organization.
Shares of Indoco Remedies fell 5.89% to Rs 233.15 on the BSE.
"Prevent unauthorised transactions in your account ; Update your mobile numbers/email IDs with Us. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day” - Issued in the interest of Investors"
"KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary."
"No need to issue cheques by investors while subscribing to Equity IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."
"Contents which are exclusively for Non-Broking Products/Services, "Mutual Fund, Mutual Fund-SIP, Research reports, Insurance, etc. where the Member is just a distributor. These are not Exchange traded product and the Member is just acting as distributor. It should also state that all disputes with respect to the distribution activity, would not have access to Exchange investor redressal forum or Arbitration mechanism."